Aridis Pharmaceuticals, Inc.
ARDS
$0.0001
$0.000.00%
OTC PK
| 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Net Income | 96.52% | 79.59% | 31.69% | 28.02% | 16.35% |
| Total Depreciation and Amortization | -43.20% | -26.90% | -6.74% | 11.95% | 49.86% |
| Total Amortization of Deferred Charges | -150.00% | -150.00% | -150.00% | -100.00% | -- |
| Total Other Non-Cash Items | -44.80% | -78.02% | -71.10% | -74.48% | -62.76% |
| Change in Net Operating Assets | -513.95% | -297.59% | -20.52% | -112.35% | -31.46% |
| Cash from Operations | 26.40% | 26.06% | 21.08% | -26.99% | 0.01% |
| Capital Expenditure | -590.00% | 52.88% | 71.76% | 84.53% | 101.10% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -450.00% | 66.35% | 71.76% | 84.53% | 101.10% |
| Total Debt Issued | -75.00% | -82.50% | -100.00% | 0.00% | -- |
| Total Debt Repaid | -530.00% | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -37.13% | -37.13% | -57.84% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | 67.11% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 6.38% | -22.56% | -40.75% | -- | -- |
| Cash from Financing | 76.09% | -57.75% | -67.46% | -57.43% | -76.93% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 83.33% | -292.56% | -479.88% | -228.19% | -224.61% |